The goal of this study was to identify molecular determinants of sensitivity and resistance to JM118, the active metabolite of satraplatin, an orally bioavailable cisplatin analog that has activity in prostate cancer.
Department of Medicine and Rebecca and John Moores UCSD Cancer Center, # 0819, University of California San Diego, 3855 Health Sciences Drive, La Jolla, CA 92093-0819, USA.
